Evidence map›Paper›PMID 30999858›Full record

ArticleBMC bioinformatics2019

Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer.

Alexander Kel, Ulyana Boyarskikh, Philip Stegmaier, Leonid S Leskov, Andrey V Sokolov, Ivan Yevshin, Nikita Mandrik, Daria Stelmashenko, Jeannette Koschmann, Olga Kel-Margoulis and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. EHMN2026Metabolites · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Transcription factor expression repertoire basis for epigenetic and transcriptional subtypes of colorectal cancers.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Alexander KelInstitute of Chemical Biology and Fundamental Medicine, SBRAN, Novosibirsk, 630090, Russia. alexander.kel@genexplain.com.
Ulyana BoyarskikhInstitute of Chemical Biology and Fundamental Medicine, SBRAN, Novosibirsk, 630090, Russia.
Philip StegmaiergeneXplain GmbH, 38302, Wolfenbüttel, Germany.
Leonid S LeskovCity Clinical Hospital №1, Novosibirsk, 630090, Russia.
Andrey V SokolovCity Clinical Hospital №1, Novosibirsk, 630090, Russia.
Ivan YevshinBiosoft.ru, Ltd, Novosibirsk, 630090, Russia.
Nikita MandrikBiosoft.ru, Ltd, Novosibirsk, 630090, Russia.
Daria StelmashenkoBiosoft.ru, Ltd, Novosibirsk, 630090, Russia.
Jeannette KoschmanngeneXplain GmbH, 38302, Wolfenbüttel, Germany.
Olga Kel-MargoulisgeneXplain GmbH, 38302, Wolfenbüttel, Germany.
Mathias KrullgeneXplain GmbH, 38302, Wolfenbüttel, Germany.
Anna Martínez-CardúsCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, Barcelona, Spain.
Sebastian MoranCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, Barcelona, Spain.
Manel EstellerCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, Barcelona, Spain.
Fedor KolpakovBiosoft.ru, Ltd, Novosibirsk, 630090, Russia.
Maxim FilipenkoInstitute of Chemical Biology and Fundamental Medicine, SBRAN, Novosibirsk, 630090, Russia.
Edgar WingendergeneXplain GmbH, 38302, Wolfenbüttel, Germany.
GeneXplain (Germany) · DEInstitute of Chemical Biology and Fundamental Medicine · RUCity Clinical Hospital No. 2 · RUInstitut d'Investigació Biomédica de Bellvitge · ESCentro de Investigación Biomédica en Red de Cáncer · ESInstitute of Computational Technologies · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe search for molecular biomarkers of early-onset colorectal cancer (CRC) is an important but still quite challenging and unsolved task. Detection of CpG methylation in human DNA obtained from blood or stool has been proposed as a promising approach to a noninvasive early diagnosis of CRC. Thousands of abnormally methylated CpG positions in CRC genomes are often located in non-coding parts of genes. Novel bioinformatic methods are thus urgently needed for multi-omics data analysis to reveal causative biomarkers with a potential driver role in early stages of cancer.

methodsWe have developed a method for finding potential causal relationships between epigenetic changes (DNA methylations) in gene regulatory regions that affect transcription factor binding sites (TFBS) and gene expression changes. This method also considers the topology of the involved signal transduction pathways and searches for positive feedback loops that may cause the carcinogenic aberrations in gene expression. We call this method "Walking pathways", since it searches for potential rewiring mechanisms in cancer pathways due to dynamic changes in the DNA methylation status of important gene regulatory regions ("epigenomic walking").

resultsIn this paper, we analysed an extensive collection of full genome gene-expression data (RNA-seq) and DNA methylation data of genomic CpG islands (using Illumina methylation arrays) generated from a sample of tumor and normal gut epithelial tissues of 300 patients with colorectal cancer (at different stages of the disease) (data generated in the EU-supported SysCol project). Identification of potential epigenetic biomarkers of DNA methylation was performed using the fully automatic multi-omics analysis web service "My Genome Enhancer" (MGE) (my-genome-enhancer.com). MGE uses the database on gene regulation TRANSFAC®, the signal transduction pathways database TRANSPATH®, and software that employs AI (artificial intelligence) methods for the analysis of cancer-specific enhancers.

conclusionsThe identified biomarkers underwent experimental testing on an independent set of blood samples from patients with colorectal cancer. As a result, using advanced methods of statistics and machine learning, a minimum set of 6 biomarkers was selected, which together achieve the best cancer detection potential. The markers include hypermethylated positions in regulatory regions of the following genes: CALCA, ENO1, MYC, PDX1, TCF7, ZNF43.

Indexed as

Feedback, PhysiologicalBinding SitesBiomarkers, TumorColorectal NeoplasmsCpG IslandsDNA MethylationEpigenesis, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm StagingSignal TransductionTranscription FactorsBiomarkers, TumorTranscription FactorsCirculating DNAColorectal cancerDNA methylationGenetic algorithmMulti-omics analysisPrognostic biomarkersSignal transductionTranscription factor binding sites

Identifiers

PMID30999858
PMCPMC6471696
OpenAlexW2936794267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.